Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
J. Fuge (Hannover, Germany), M. Richter (Gießen, Germany), H. Gall (Gießen, Germany), A. Ghofrani (Gießen, Germany), M. Hoeper (Hannover, Germany), K. Olsson (Hannover, Germany). Assessment of quality of life and social and economic impact of the disease in patients with pulmonary arterial hypertension in Germany – Data of the SANTANA-Study. 1518

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension: the burden of disease and impact on quality of life Source: Eur Respir Rev 2015; 24: 621-629 Year: 2015 Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 The influence of psycho-social factors in the evolution of pulmonary hypertension patients Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Impact of Sars-CoV-2-Pandemic on mental disorders and quality of life in patients with pulmonary arteriaI hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Relationship of quality of life and life expectancy with tolerance to physical exercises and cardio respiratory parameters in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR Source: Eur Respir J, 57 (2) 2000414; 10.1183/13993003.00414-2020 Year: 2021 Links between psychological factors and health-related quality of life in pulmonary hypertension Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension Source: Eur Respir J 2014; 43: 1106-1113 Year: 2014 Relation of the novel pulmonary hypertension emPHasis10 quality of life score to markers of disease severity Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study Source: ERJ Open Res, 7 (3) 00617-2020; 10.1183/23120541.00617-2020 Year: 2021 Health-related quality of life in patients with pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Quality of life and physical functioning in chronic thromboembolic pulmonary hypertension (CTEPH):  the impact of treatment Source: International Congress 2017 – PAH and CTEPH Year: 2017 Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Community pulmonary rehabilitation for COPD: physical, psychological and quality of life improvements are independent of age and disease severity Source: Eur Respir J 2007; 30: Suppl. 51, 93s Year: 2007 Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension Source: Eur Respir J 2011; 38: 608-616 Year: 2011 Measurement of quality of life in pulmonary hypertension and its significance Source: Eur Respir J 2006 Oct 01;28(4):808-815 Year: 2006